BAJAJ BROKING
The US FDA has restricted imports of 11 Viatris drugs made in India, citing violations of federal regulations. Exceptions apply to four drugs due to shortage concerns. Viatris is addressing these issues with a comprehensive remediation plan.
The United States Food and Drug Administration (US FDA) has issued a warning letter to Viatris regarding its drug manufacturing facility in Indore, Madhya Pradesh. Following an inspection, the agency identified violations of federal requirements, leading to the restriction of imports for 11 products manufactured at the facility. The impacted drugs, primarily oral finished doses like tablets and capsules, will not be accepted into the United States until the warning letter is resolved.
Also read: Adani Defence Acquires 85.8% Stake in Air Works for ₹400 Crore
Action: US FDA restricted imports of 11 Viatris products.
Reason: Federal violations identified at the Indore facility.
Exceptions: Four drugs allowed conditionally due to shortages.
Remediation: Viatris implemented corrective actions and engaged independent experts.
Also read: TVS Motor Acquires Majority Stake in DriveX with 87.38% Holding
The 11 restricted products, whose specifics have not been disclosed, are key oral medications catering to therapeutic areas such as antibacterials, diabetes management, and cardiovascular health. The restriction poses challenges for Viatris, formed through the merger of Mylan and Pfizer's off-patent drug business. The company operates four manufacturing sites in India, which play a vital role in its global supply chain.
To address potential shortages, the US FDA has granted conditional exceptions for four products, allowing them to be imported. Additional exceptions may be considered after further discussions.
In response to the warning letter, Viatris has committed to submitting a detailed plan within the required time frame. The company has implemented corrective and preventive actions at the Indore facility, supported by independent third-party experts.
The following table summarises the key details:
Aspect | Details |
Facility Location | Indore, Madhya Pradesh, India |
Restricted Products | 11 oral finished doses (tablets, capsules) |
Conditional Exceptions | 4 products due to shortage concerns |
Therapeutic Categories | Antibacterials, diabetes, cardiovascular therapies |
The import restrictions highlight regulatory scrutiny in pharmaceutical manufacturing. As Viatris works on resolving these issues, its stock performance may be impacted. Monitoring the Mylan share price and Pfizer share price could provide insights into investor sentiment as the company remediates its compliance concerns.
The US FDA’s import restrictions on Viatris drugs underscore the importance of compliance with manufacturing regulations. While the company addresses the violations, conditional exceptions for some drugs may mitigate the immediate impact.
Also read: BEL Secures Orders Worth ₹973 Crore, Achieves 40% of FY25 Target
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Price in India | Gold Prices Gain as Dollar and Yields Ease
24 Dec, 2024 | 40 Min. read
TVS Motor Acquires Majority Stake in DriveX with 87.38% Holding
24 Dec, 2024 | 2 Min. read
Share Market Today | Gift Nifty Hints At Flat Opening; Nifty Likely In 23,600-23,900
24 Dec, 2024 | 4 Min. read
Adani Defence Acquires 85.8% Stake in Air Works for ₹400 Crore
24 Dec, 2024 | 2 Min. read
BEL Secures Orders Worth ₹973 Crore, Achieves 40% of FY25 Target
24 Dec, 2024 | 2 Min. read
US FDA Restricts Imports of Viatris Drugs Manufactured at Indian Facility
24 Dec, 2024 | 2 Min. read
NTPC Green Energy Partners with Bihar for Renewable Energy Push
23 Dec, 2024 | 2 Min. read
NHPC to Invest ₹5,500 Crore in Bihar for Solar, Green Hydrogen
23 Dec, 2024 | 2 Min. read
Piramal Enterprises Approves ₹2,000 Crore Fundraising Plan
23 Dec, 2024 | 2 Min. read
NSE to Exclude 16 Securities from F&O Contracts by Feb 28
23 Dec, 2024 | 2 Min. read
Share Market Today | Gift Nifty Hints At A Positive Start For Indian Markets
23 Dec, 2024 | 4 Min. read
How to Apply for Unimech Aerospace IPO & Check Allotment Status?
23 Dec, 2024 | 3 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading